Phase II evaluation of mitozolomide in ovarian cancer.
作者信息
Harding M, Northcott D, Smyth J, Stuart N S, Green J A, Newlands E
机构信息
Department of Medical Oncology, Gartnavel General Hospital, Glasgow, UK.
出版信息
Br J Cancer. 1988 Jan;57(1):113-4. doi: 10.1038/bjc.1988.21.
Abstract
摘要
相似文献
1
Phase II evaluation of mitozolomide in ovarian cancer.卵巢癌中米托蒽醌的II期评估。 （注：原文中mitozolomide应为mitoxantrone，即米托蒽醌 ）
Br J Cancer. 1988 Jan;57(1):113-4. doi: 10.1038/bjc.1988.21.
2
A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder.一项关于米托唑胺治疗转移性膀胱移行细胞癌的II期研究。
Eur J Cancer Clin Oncol. 1989 Feb;25(2):391-2. doi: 10.1016/0277-5379(89)90036-9.
3
Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative Group.米托唑胺治疗晚期卵巢癌患者的II期试验。欧洲癌症研究与治疗组织妇科癌症合作组的一项研究。
Acta Oncol. 1989;28(5):663-5. doi: 10.3109/02841868909092290.
4
[1st experiences in the treatment of ovarian tumors with Peptichemio].[使用胃蛋白酶抑制剂治疗卵巢肿瘤的首次经验]
Minerva Med. 1974 May 2;65(33):1805-10.
5
Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group.
Eur J Cancer. 1992;28A(4-5):855-7. doi: 10.1016/0959-8049(92)90132-l.
6
Phase II studies of mitozolomide in melanoma, lung and ovarian cancer.米托唑胺用于黑色素瘤、肺癌和卵巢癌的II期研究。
Eur J Cancer Clin Oncol. 1989 May;25(5):785-8. doi: 10.1016/0277-5379(89)90121-1.
7
[The results of a clinical study of asafan].[阿萨凡的临床研究结果]
Vopr Onkol. 1970 May;16(5):41-5.
8
Abbreviated phase I clinical trial of i.v. mitozolomide.静脉注射米托唑胺的简化I期临床试验。
Cancer Treat Rep. 1986 Jun;70(6):797-8.
9
Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.米托唑胺治疗晚期肾癌。欧洲癌症研究与治疗组织泌尿生殖系统癌症合作组针对既往未接受治疗患者的一项II期研究。
Eur J Cancer Clin Oncol. 1989 Aug;25(8):1249-50. doi: 10.1016/0277-5379(89)90422-7.
10
Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer.米托唑胺（M&B 39,565）用于结直肠癌和乳腺癌的II期研究。
Invest New Drugs. 1988 Dec;6(4):323-5. doi: 10.1007/BF00173652.
引用本文的文献
1
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.KL-50，一种用于治疗耐药性脑癌的咪唑并四嗪候选药物的作用机制。
J Am Chem Soc. 2024 Jul 10;146(27):18241-18252. doi: 10.1021/jacs.3c06483. Epub 2024 May 30.
2
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.替莫唑胺及其他烷化剂在胶质母细胞瘤治疗中的应用
Biomedicines. 2019 Sep 9;7(3):69. doi: 10.3390/biomedicines7030069.
3
Relationship between the pharmacokinetics and toxicity of mitozolomide.米托唑胺的药代动力学与毒性之间的关系。
Cancer Chemother Pharmacol. 1990;25(5):352-4. doi: 10.1007/BF00686236.
4
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).替莫唑胺的I期试验（CCRG 81045：M&B 39831：NSC 362856）。
Br J Cancer. 1992 Feb;65(2):287-91. doi: 10.1038/bjc.1992.57.
5
A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue.
Cancer Chemother Pharmacol. 1992;29(3):201-6. doi: 10.1007/BF00686253.
本文引用的文献
1
Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent.抗肿瘤咪唑并四嗪类化合物。1. 新型广谱抗肿瘤药物8-氨基甲酰基-3-(2-氯乙基)咪唑并[5,1-d]-1,2,3,5-四嗪-4(3H)-酮的合成与化学性质
J Med Chem. 1984 Feb;27(2):196-201. doi: 10.1021/jm00368a016.
2
Phase I clinical trial of mitozolomide.米托唑胺的I期临床试验。
Cancer Treat Rep. 1985 Jul-Aug;69(7-8):801-5.
3
4
Common epithelial cancer of the ovary (2).常见的卵巢上皮性癌（2）。
N Engl J Med. 1985 Feb 21;312(8):474-83. doi: 10.1056/NEJM198502213120804.
5
Mitozolomide activity on human cancer cells in vitro.米托唑胺对人癌细胞的体外活性。
Br J Cancer. 1986 Dec;54(6):925-32. doi: 10.1038/bjc.1986.263.
Zotero 插件